In a study, chronic kidney disease was nearly twice as likely to develop in patients who had post-operative complications following nephron-sparing surgery.
Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.
About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.
Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.
New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.
Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.
As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.
Kidney cancer and some other cancers tied to obesity are increasing the most rapidly among individuals younger than 50.
First-line treatment of metastatic renal cell carcinoma with tyrosine kinase inhibitors is associated with worse progression-free and overall survival in patients with non-clear-cell vs clear-cell histology.
Evidence suggests that starting on systemic drug therapy immediately may be the best approach for some patients with metastatic RCC.
Routine partial nephrectomy yielded longest life expectancy in patients with normal renal function.
A history of kidney stones is associated with an increased risk of papillary renal cell carcinoma and upper tract urothelial carcinoma, according to a large prospective study.
In a small study, sunitinib recipients who took royal jelly, a substance produced by worker honeybees for queen bees, were less likely to experience fatigue and anorexia than those who took placebo.
Researchers theorize that KPNA2 expression could be used in the future to stratify risk groups among patients with renal cell carcinoma (RCC).
A review article examines the challenges in pathologic staging and grade reporting for patients with renal cell carcinoma.
Incredible progress is being made in kidney cancer treatment.
Lymph node dissection did not influence overall survival even among patients with clinically positive nodal disease.
Avelumab plus axitinib is associated with longer progression-free survival compared with sunitinib as first-line therapy in patients with advanced renal cell carcinoma.
Local control, cancer-specific survival at 2 years similar for patients with solitary, bilateral kidneys
At the time of diagnosis of renal cell carcinoma, blacks had 33% lower odds of regional disease compared with whites, a new study found.
Australian study shows that end-stage renal disease develops in 1.7% of patients with 3 years of undergoing nephrectomy for kidney cancer.
Study of patients with clinical T1a renal cell carcinoma shows that those who undergo renal mass biopsy have only a 1.2% rate of upstaging to pT3a perinephric fat involvement.
Propensity score-matched analysis shows that radical and partial nephrectomy for cT1 renal cell carcinoma are associated with similar cancer-specific and all-cause mortality, a study found.
Older age, male sex, and higher T stage are associated with an increased risk of having bone metastases at initial diagnosis of renal cell carcinoma, study finds.
Partial vs radical nephrectomy is associated with an overall survival advantage among patients with RCC tumors 4 cm or smaller and many patients with larger tumors.
A neutrophil-lymphocyte ratio below 4 is associated with significantly longer survival among patients with non-poor-risk metastatic renal cell carcinoma.
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
In a German study of patients starting first-line systemic therapy for advanced renal cell carcinoma, patients with a low BMI were twice as likely to die as those with a high BMI.
Prospective study at Johns Hopkins shows excellent oncologic outcomes and preserved mental quality of life for all patients regardless of management strategy, with worse renal function after radical nephrectomy.
A "weekday-on and weekend-off regimen" improves relative dose intensity compared with the conventional regimen, a study found.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)